Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 84
Filter
Add more filters

Publication year range
1.
Antimicrob Agents Chemother ; 68(1): e0096823, 2024 Jan 10.
Article in English | MEDLINE | ID: mdl-38084953

ABSTRACT

Antifungal susceptibility testing (AST) is crucial in clinical settings to guide appropriate therapy. Nevertheless, discrepancies between treatment response and some results still persist, particularly in detecting resistance to amphotericin B (AMB) in Clavispora (Candida) lusitaniae. This study aimed to assess the susceptibility patterns of 48 recent isolates of C. lusitaniae to 9 antifungal agents and explore the feasibility of using a CLSI reference-based method to identify AMB resistance. Microdilution techniques revealed a wide range of minimal inhibitory concentration (MIC) values for azole antifungals, while echinocandins and AMB exhibited a narrow range of MIC values, with all strains considered wild-type for the tested polyene and echinocandins. However, when agar diffusion (ellipsometry) was employed for AST, certain strains displayed colonies within the inhibition ellipse, indicating potential resistance. Interestingly, these strains did not respond to AMB treatment and were isolated during AMB treatment (breakthrough). Moreover, the evaluation of AMB minimum fungicidal concentrations (MFCs) indicated that only the strains with colonies inside the ellipse had MFC/MIC ratios ≥ 4, suggesting reduced fungicidal activity. In conclusion, this study confirms the effectiveness of ellipsometry with RPMI-1640 2% glucose agar for detecting AMB resistance in C. lusitaniae. Additionally, the proposed approach of culturing "clear" wells in the microdilution method can aid in uncovering resistant strains. The findings highlight the importance of appropriate AST methods to guide effective treatment strategies for deep-seated candidiasis caused by C. lusitaniae. Further collaborative studies are warranted to validate these findings and improve the detection of AMB clinical resistance.


Subject(s)
Amphotericin B , Antifungal Agents , Amphotericin B/pharmacology , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Candida , Agar/pharmacology , Echinocandins/pharmacology , Microbial Sensitivity Tests
2.
Med Mycol ; 62(7)2024 Jul 04.
Article in English | MEDLINE | ID: mdl-38744661

ABSTRACT

The second international meeting on endemic mycoses of the Americas (IMEMA) and the first international symposium on implantation mycoses (ISIM) took place in Santiago del Estero, Argentina, on September 25-27, 2023. The conference provided a platform for researchers, clinicians, and experts to discuss the latest developments in the field of endemic and implantation mycoses. Topics included epidemiology, diagnostic advances, treatment strategies, and the impact of environmental factors on the spread of these fungal diseases. IMEMA and ISIM contributed to the regional discourse on the mycoses, emphasizing the importance of international cooperation in addressing these public health challenges.


IMEMA/ISIM, held in Santiago del Estero, Argentina, convened experts to discuss endemic and implantation mycoses, covering topics such as epidemiology, diagnostics, treatment, and advocacy. The event highlighted ongoing efforts in combating these diseases.


Subject(s)
Endemic Diseases , Mycoses , Humans , Mycoses/epidemiology , Mycoses/microbiology , Americas/epidemiology , Argentina/epidemiology , Prosthesis-Related Infections/microbiology , Prosthesis-Related Infections/epidemiology
3.
Mycoses ; 67(7): e13757, 2024 Jul.
Article in English | MEDLINE | ID: mdl-39049157

ABSTRACT

BACKGROUND: Candida vulturna is an emerging pathogen belonging to the Metshnikowiaceae family together with Candida auris and Candida haemulonii species complex. Some strains of this species were reported to be resistant to several antifungal agents. OBJECTIVES: This study aims to address identification difficulties, evaluate antiungal susceptibilities and explore the molecular mechanisms of azole resistance of Candida vulturna. METHODS: We studied five C. vulturna clinical strains isolated in three Colombian cities. Identification was performed by phenotypical, proteomic and molecular methods. Antifungal susceptibility testing was performed following CLSI protocol. Its ERG11 genes were sequenced and a substitution was encountered in azole resistant isolates. To confirm the role of this substitution in the resistance phenotype, Saccharomyces cerevisiae strains with a chimeric ERG11 gene were created. RESULTS: Discrepancies in identification methods are highlighted. Sequencing confirmed the identification as C. vulturna. Antifungal susceptibility varied among strains, with four strains exhibiting reduced susceptibility to azoles and amphotericin B. ERG11 sequencing showed a point mutation (producing a P135S substitution) that was associated with the azole-resistant phenotype. CONCLUSIONS: This study contributes to the understanding of C. vulturna's identification challenges, its susceptibility patterns, and sheds light on its molecular mechanisms of azole resistance.


Subject(s)
Antifungal Agents , Azoles , Candida , Candidiasis , Microbial Sensitivity Tests , Antifungal Agents/pharmacology , Azoles/pharmacology , Candida/drug effects , Candida/genetics , Candida/classification , Candida/isolation & purification , Candidiasis/microbiology , Humans , Drug Resistance, Multiple, Fungal/genetics , Colombia , Amphotericin B/pharmacology , Drug Resistance, Fungal/genetics , Point Mutation , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/drug effects , Cytochrome P-450 Enzyme System/genetics , Fungal Proteins/genetics , Sequence Analysis, DNA , Saccharomyces cerevisiae Proteins
4.
Rev Argent Microbiol ; 2024 Sep 02.
Article in Spanish | MEDLINE | ID: mdl-39227267

ABSTRACT

Intestinal parasitic diseases constitute a cosmopolitan public health concern, with greater prevalence in developing countries, and mainly affecting children. The aim of this study was to develop an educational intervention aimed at mothers/guardians of children attending three child development centers (CDI) in Santa Fe, Argentina, during 2018. An educational intervention was conducted using a descriptive, quasi-experimental design, with pre- and post-intervention assessment. This intervention included 36 mothers, and was carried out in three stages: diagnosis, intervention and final evaluation. Simultaneously, a coproparasitological study was performed on 48 children under 5 years of age, who were assisted in the CDI, with the aim to understand and address the parasitic infections prevalent in the child population. It was possible to compare the correct answers before and after the educational intervention, observing a statistically significant increase (p=0.008742) in the average number of correct answers. Enteroparasites were identified in 54% of the population of children analyzed, 10% were biparasitized and 6% had more than two parasitic species. The most frequently detected parasites were Blastocystis spp., Giardia intestinalis and Ascaris lumbricoides. The educational intervention was positive, resulting in an improvement in the level of knowledge related to intestinal parasitosis and its prevention. This educational intervention experience highlights the importance of ongoing education in promoting a healthy lifestyle and preventing parasitosis in vulnerable populations.

5.
Med Mycol ; 61(8)2023 Aug 02.
Article in English | MEDLINE | ID: mdl-37591630

ABSTRACT

In cystic fibrosis (CF) patients, fungal colonization of the respiratory tract is frequently found. Aspergillus fumigatus, Scedosporium genus, and Exophiala dermatitidis are the most commonly isolated moulds from the respiratory tract secretions of CF patients. The aim of this 5-year surveillance study was to identify trends in species distribution and susceptibility patterns of 212 mould strains identified as Aspergillus spp., Scedosporium spp., and Exophiala spp., isolated from sputum of 63 CF patients who received long-term therapy with itraconazole (ITR) and/or voriconazole (VRC). The Aspergillus isolates were identified as members of the sections Fumigati (n = 130), Flavi (n = 22), Terrei (n = 20), Nigri (n = 8), Nidulantes (n = 1), and Usti (n = 1). Among the 16 species of the genus Scedosporium, 9 were S. apiospermum, 3 S. aurantiacum, and 4 S. boydii. Among the 14 Exophiala species, all were molecularly identified as E. dermatitidis. Overall, 94% (15/16) of Scedosporium spp., 50% (7/14) of E. dermatitidis, and 7.7% (14/182) of Aspergillus spp. strains showed high MIC values (≥8 µg/ml) for at least one antifungal. Particularly, 8.9% (19/212) of isolates showed high MIC values for amphotericin B, 11.7% (25/212) for ITR, 4.2% (9/212) for VRC, and 3.3% (7/212) for posaconazole. In some cases, such as some A. fumigatus and E. dermatitidis isolates recovered from the same patient, susceptibility to antifungal azoles decreased over time. We show that the use of azoles for a long time in CF patients causes the selection/isolation of mould strains with higher MIC values.


The use of azoles for a long time in cystic fibrosis patients causes the selection/isolation of Aspergillus, Scedosporium, and Exophiala species with higher MIC values.


Subject(s)
Cystic Fibrosis , Exophiala , Scedosporium , Animals , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Amphotericin B/pharmacology , Amphotericin B/therapeutic use , Cystic Fibrosis/complications , Cystic Fibrosis/veterinary , Exophiala/genetics , Triazoles/pharmacology , Triazoles/therapeutic use , Itraconazole , Voriconazole/pharmacology , Voriconazole/therapeutic use , Aspergillus , Azoles
6.
Rev Argent Microbiol ; 55(2): 120-128, 2023.
Article in English | MEDLINE | ID: mdl-36682905

ABSTRACT

The high load of agrochemicals and antibiotics present in agricultural aquatic environments represents a risk for wildlife. Since enteric bacteria, which play a key role in the physiological functioning of their hosts, are sensitive to a wide variety of pollutants, their study allows to evaluate the health of organisms. This study aimed to evaluate the effects of commercial formulations of a glyphosate-based herbicide (GBH) and the antibiotic ciprofloxacin (CIP), individually and in mixture, on the bacterial diversity of the intestinal content of common toad (Rhinella arenarum) tadpoles. The diversity of cultivable fast-growing bacteria with low nutritional requirements was evaluated using classic microbiological tests and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry identification. Bacterial diversity varied among treatments. Taxa diversity increased in the GBH-treated group but decreased in the CIP-treated group. Remarkably, Yersinia spp. and Proteus spp. were only found in the GBH-treated group. The prevalence of Klebsiella spp. and Pseudomonas spp. decreased in the intestinal microbiota of the GBH-CIP-treated group. To our knowledge, this is the first report on the alteration of cultivable enteric bacteria of autochthonous tadpoles due to two pollutants of emerging concern. Our results demonstrate that R. arenarum tadpoles can be used as non-conventional model organisms for environmental pollution monitoring. Our preliminary findings would contribute to understanding how the presence of GBH and CIP in freshwaters may represent a threat to wildlife and human health by causing enteric dysbiosis of part of the bacterial community.


Subject(s)
Gastrointestinal Microbiome , Herbicides , Animals , Humans , Larva , Ciprofloxacin/adverse effects , Herbicides/pharmacology , Enterobacteriaceae , Anti-Bacterial Agents/adverse effects , Glyphosate
7.
Med Mycol ; 2022 Oct 08.
Article in English | MEDLINE | ID: mdl-36208938

ABSTRACT

Candida auris is considered a public health problem due to its resistance and its tendency to cause nosocomial outbreaks. CHROMagarTMCandida Plus has recently been marketed as capable of presumptively identifying C. auris. The objective of this work was to analyze the ability of this new chromogenic medium to differentiate C. auris from other members of the C. haemulonii complex and from other yeasts commonly isolated in clinical practice. A collection of 220 strains including species of the C. haemulonii (n = 83) and C. parapsilosis (n = 80) complexes was studied. The strains were identified by molecular methods and cultured as individual or as mixed aqueous inoculum on CHROMagarTMCandida Plus plates. Colony morphotypes were evaluated at 5 time points. CHROMagarTMCandida Plus was a helpful tool for presumptive identification for C. auris. Better reading results were obtained after 48 hours of incubation at 35°C. It is able to easily differentiate C. auris from other closely related species of the C. haemulonii complex and other yeasts. This chromogenic medium would be also useful as screening and surveillance tool for C. auris colonization. However, we demonstrated that it would be a possible misidentification of C. parapsilosis as C. auris (44.3% showed similar morphotypes). To reduce false positives when it is used in a context of a C. auris outbreak, we propose to supplement the chromogenic medium with 8 µg/ml fluconazole. This modified medium was tested and it clearly differentiate C. parapsilosis from C. auris.


CHROMagarTMCandida Plus is able to differentiate C. auris from other Candida spp., including other species of the C. haemulonii complex. However, 44.3% of the tested C. parapsilosis strains would be misidentified as C. auris. We propose the addition of 8 µg/ml fluconazole to solve this issue.

8.
Med Mycol ; 60(5)2022 May 18.
Article in English | MEDLINE | ID: mdl-35394043

ABSTRACT

COVID-19-associated pulmonary aspergillosis (CAPA) incidence varies depending on the country. Serum galactomannan quantification is a promising diagnostic tool since samples are easy to obtain with low biosafety issues. A multicenter prospective study was performed to evaluate the CAPA incidence in Argentina and to assess the performance of the lateral flow assay with digital readout (Sona Aspergillus LFA) as a CAPA diagnostic and screening tool. The correlation between the values obtained with Sona Aspergillus LFA and Platelia® EIA was evaluated. In total, 578 serum samples were obtained from 185 critically ill COVID patients. CAPA screening was done weekly starting from the first week of ICU stay. Probable CAPA incidence in critically ill patients was 10.27% (19/185 patients when LFA was used as mycological criteria) and 9% (9/100 patients when EIA was used as mycological criteria). We found a very good correlation between the two evaluated galactomannan quantification methods (overall agreement of 92.16% with a Kappa statistic value of 0.721). CAPA diagnosis (>0.5 readouts in LFA) were done during the first week of ICU stay in 94.7% of the probable CAPA patients. The overall mortality was 36.21%. CAPA patients' mortality and length of ICU stay were not statistically different from for COVID (non-CAPA) patients (42.11 vs 33.13% and 29 vs 24 days, respectively). These indicators were lower than in other reports. LFA-IMMY with digital readout is a reliable tool for early diagnosis of CAPA using serum samples in critically ill COVID patients. It has a good agreement with Platelia® EIA. LAY SUMMARY: The incidence of COVID-associated pulmonary aspergillosis (CAPA) in critically-ill Argentinian patients was established (10.27%). Serum galactomannan quantification was useful as a screening tool for this mycosis. A good agreement between Platelia® EIA and Sona Aspergillus LFA is reported.


Subject(s)
COVID-19 , Invasive Pulmonary Aspergillosis , Pulmonary Aspergillosis , Animals , Argentina/epidemiology , Aspergillus , COVID-19/diagnosis , COVID-19/veterinary , Critical Illness , Galactose/analogs & derivatives , Humans , Invasive Pulmonary Aspergillosis/diagnosis , Invasive Pulmonary Aspergillosis/veterinary , Mannans , Prospective Studies , Pulmonary Aspergillosis/diagnosis , Pulmonary Aspergillosis/veterinary , Sensitivity and Specificity
9.
Rev Argent Microbiol ; 54(1): 9-14, 2022.
Article in Spanish | MEDLINE | ID: mdl-33875292

ABSTRACT

We evaluated the interlaboratory agreement, the essential agreement, and the categorical agreement between the Sensititre YeastOneTM panel and the reference methods M27 4th Edition of the Clinical and Laboratory Standards Institute (CLSI), and the EDef 7.3.1 of the European Committee on Antifungal Susceptibility Testing (EUCAST). We studied 67 Candida strains isolated from different clinical samples and 9 Candida strains with resistance to fluconazole and echinocandins. The highest percentage of interlaboratory agreement was observed with amphotericin B (96.8%), and the lowest percentage with voriconazole (77.2%). Caspofungin showed 5.8% of very major errors when compared with the CLSI reference method. For EUCAST, itraconazole, posaconazole, and anidulafungin showed high percentages of major errors: 17.6%, 18.1%, and 19.6%, respectively. Sensititre YeastOneTM is a reliable alternative, and easy to perform for detecting Candida species resistant to antifungal drugs, with some limitations for echinocandins. Results are comparable to those of the reference methods.


Subject(s)
Candida , Candidiasis , Antifungal Agents/pharmacology , Candidiasis/microbiology , Echinocandins , Humans , Microbial Sensitivity Tests
10.
Med Mycol ; 59(12): 1202-1209, 2021 Dec 03.
Article in English | MEDLINE | ID: mdl-34550395

ABSTRACT

Rhizopus oryzae (heterotypic synonym: R. arrhizus) intrinsic voriconazole and fluconazole resistance has been linked to its CYP51A gene. However, the amino acid residues involved in this phenotype have not yet been established. A comparison between R. oryzae and Aspergillus fumigatus Cyp51Ap sequences showed differences in several amino acid residues. Some of them were already linked with voriconazole resistance in A. fumigatus. The objective of this work was to analyze the role of two natural polymorphisms in the intrinsic voriconazole resistance phenotype of R. oryzae (Y129F and T290A, equivalent to Y121F and T289A seen in triazole-resistant A. fumigatus). We have generated A. fumigatus chimeric strains harboring different R. oryzae CYP51A genes (wild-type and mutants). These mutant R. oryzae CYP51A genes were designed to carry nucleotide changes that produce mutations at Cyp51Ap residues 129 and 290 (emulating the Cyp51Ap protein of azole susceptible A. fumigatus). Antifungal susceptibilities were evaluated for all the obtained mutants. The polymorphism T290A (alone or in combination with Y129F) had no impact on triazole MIC. On the other hand, a > 8-fold decrease in voriconazole MICs was observed in A. fumigatus chimeric strains harboring the RoCYP51Ap-F129Y. This phenotype supports the assumption that the naturally occurring polymorphism Y129F at R. oryzae Cyp51Ap is responsible for its voriconazole resistance phenotype. In addition, these chimeric mutants were posaconazole hypersusceptible. Thus, our experimental data demonstrate that the RoCYP51Ap-F129 residue strongly impacts VRC susceptibility and that it would be related with posaconazole-RoCYP51Ap interaction. LAY SUMMARY: Rhizopus oryzae is intrinsically resistant to voriconazole, a commonly used antifungal agent. In this work, we analyze the role of two natural polymorphisms present in the target of azole drugs. We established that F129 residue is responsible of the intrinsic voriconazole resistance in this species.


Subject(s)
Aspergillus fumigatus , Drug Resistance, Fungal , Animals , Antifungal Agents/pharmacology , Aspergillus fumigatus/genetics , Azoles , Cytochrome P-450 Enzyme System/genetics , Drug Resistance, Fungal/genetics , Fungal Proteins/genetics , Microbial Sensitivity Tests/veterinary , Rhizopus oryzae , Voriconazole/pharmacology
11.
Article in English | MEDLINE | ID: mdl-32423948

ABSTRACT

The treatment of invasive and chronic aspergillosis involves triazole drugs. Its intensive use has resulted in the selection of resistant isolates, and at present, azole resistance in Aspergillus fumigatus is considered an emerging threat to public health worldwide. The aim of this work is to uncover the molecular mechanism implicated in the azole resistance phenotype of three Aspergillus fumigatus clinical strains isolated from an Argentinian cystic fibrosis patient under long-term triazole treatment. Strain susceptibilities were assessed, and CYP51A gene sequences were analyzed. Two of the studied Aspergillus fumigatus strains harbored the TR34-L98H allele. These strains showed high MIC values for all tested triazoles (>16.00 µg/ml, 1.00 µg/ml, 1.00 µg/ml, and 2.00 µg/ml for itraconazole, isavuconazole, posaconazole, and voriconazole, respectively). The third strain had a novel amino acid change (R65K) combined with the TR34-L98H mutations. This new mutation combination induces a pan-azole MIC augment compared with TR34-L98H mutants (>16 µg/ml, 4.00 µg/ml, 4.00 µg/ml, and 8.00 µg/ml for itraconazole, isavuconazole, posaconazole, and voriconazole, respectively). The strain harboring the TR34-R65K-L98H allele showed no inhibition halo when voriconazole susceptibility was evaluated by disk diffusion. The effect of these mutations in the azole-resistant phenotype was confirmed by gene replacement experiments. Transformants harboring the TR34-L98H and TR34-R65K-L98H alleles mimicked the azole-resistant phenotype of the clinical isolates, while the incorporation of the TR34-R65K and R65K alleles did not significantly increase azole MIC values. This is the first report of the TR34-L98H allele in Argentina. Moreover, a novel CYP51A allele (TR34-R65K-L98H) that induces a pan-azole MIC augment is described.


Subject(s)
Aspergillus fumigatus , Azoles , Fungal Proteins , Antifungal Agents/pharmacology , Argentina , Aspergillus fumigatus/genetics , Azoles/pharmacology , Cytochrome P-450 Enzyme System , Drug Resistance, Fungal/genetics , Fungal Proteins/genetics , Humans , Microbial Sensitivity Tests , Mutation
12.
Mycoses ; 63(9): 937-941, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32648614

ABSTRACT

BACKGROUND: Triazole resistance in Aspergillus fumigatus sensu stricto due to mutations in the cyp51A gene has been widely reported. Data from Argentina, and particularly from cystic fibrosis (CF) patients, are limited. OBJECTIVES: To investigate the prevalence and molecular mechanisms of azole resistance in A. fumigatus sensu stricto recovered from this population. METHODS: Ninety-three A. fumigatus isolates from 50 CF patients were retrospectively analysed for azole resistance using the standard microbroth dilution method according to CLSI M38-A2 guidelines. Sequencing analysis of the cyp51A gene and its promoter region was conducted in those isolates displaying high MIC values to itraconazole, voriconazole and/or posaconazole. RESULTS: Overall, 14% of isolates displayed high MIC values to at least one azole. Of them, 30.7% had the mutation TR34-L98H. No mutations in the cyp51A gene or its promoter were found in the remaining non-wild-type strains. Therefore, other mechanisms associated with azole resistance can be highly prevalent in these isolates. CONCLUSIONS: To the best of our knowledge, this is the first study in Latin America reporting azole-resistant A. fumigatus strains recovered from respiratory secretions of CF patients. Noteworthy, the prevalence of azole resistance in A. fumigatus sensu stricto in the studied Argentinean CF population is alarmingly high.


Subject(s)
Antifungal Agents/pharmacology , Aspergillosis/epidemiology , Aspergillus fumigatus/drug effects , Cystic Fibrosis/complications , Triazoles/pharmacology , Adolescent , Adult , Argentina/epidemiology , Aspergillosis/etiology , Aspergillus fumigatus/genetics , Child , Cystic Fibrosis/epidemiology , Cystic Fibrosis/microbiology , Drug Resistance, Fungal/genetics , Humans , Microbial Sensitivity Tests , Middle Aged , Mutation , Prevalence , Retrospective Studies , Sequence Analysis, DNA , Sputum/microbiology , Young Adult
13.
Article in English | MEDLINE | ID: mdl-30885898

ABSTRACT

Mucormycosis is an emerging disease with high mortality rates. Few antifungal drugs are active against Mucorales. Considering the low efficacy of monotherapy, combination-therapy strategies have been described. It is known that fungi are susceptible to zinc deprivation, so we tested the in vitro effect of the zinc chelators clioquinol, phenanthroline, and N,N,N',N'-tetrakis(2-pyridylmethyl)ethane-1,2-diamine combined with amphotericin B or posaconazole against 25 strains of Mucorales. Clioquinol-posaconazole was the most active combination, although results were strain dependent.


Subject(s)
Amphotericin B/pharmacology , Antifungal Agents/pharmacology , Chelating Agents/pharmacology , Mucorales/drug effects , Triazoles/pharmacology , Zinc/chemistry , Clioquinol/pharmacology , Microbial Sensitivity Tests , Phenanthrolines/pharmacology
14.
J Antimicrob Chemother ; 74(8): 2295-2302, 2019 08 01.
Article in English | MEDLINE | ID: mdl-31081031

ABSTRACT

BACKGROUND: Candida auris is an emerging MDR pathogen. It shows reduced susceptibility to azole drugs and, in some strains, high amphotericin B MICs have been described. For these reasons, echinocandins were proposed as first-line treatment for C. auris infections. However, information on how echinocandins and amphotericin B act against this species is lacking. OBJECTIVES: Our aim was to establish the killing kinetics of anidulafungin, caspofungin and amphotericin B against C. auris by time-kill methodology and to determine if these antifungals behave as fungicidal or fungistatic agents against this species. METHODS: The susceptibility of 50 C. auris strains was studied. Nine strains were selected (based on echinocandin MICs) to be further studied. Minimal fungicidal concentrations, in vitro dose-response and time-kill patterns were determined. RESULTS: Echinocandins showed lower MIC values than amphotericin B (geometric mean of 0.12 and 0.94 mg/L, respectively). Anidulafungin and caspofungin showed no fungicidal activity at any concentration (maximum log decreases in cfu/mL between 1.34 and 2.22). On the other hand, amphotericin B showed fungicidal activity, but at high concentrations (≥2.00 mg/L). In addition, the tested polyene was faster than echinocandins at killing 50% of the initial inoculum (0.92 versus >8.00 h, respectively). CONCLUSIONS: Amphotericin B was the only agent regarded as fungicidal against C. auris. Moreover, C. auris should be considered tolerant to caspofungin and anidulafungin considering that their MFC:MIC ratios were mostly ≥32 and that after 6 h of incubation the starting inoculum was not reduced in >90%.


Subject(s)
Amphotericin B/pharmacology , Anidulafungin/pharmacology , Antifungal Agents/pharmacology , Candida/drug effects , Caspofungin/pharmacology , Microbial Viability/drug effects , Microbial Sensitivity Tests , Time Factors
15.
Article in English | MEDLINE | ID: mdl-29891608

ABSTRACT

Rhizopus oryzae is the most prevalent causative agent of mucormycosis, an increasingly reported opportunistic fungal infection. These Mucorales are intrinsically resistant to Candida- and Aspergillus-active antifungal azole drugs, such as fluconazole (FLC) and voriconazole, respectively. Despite its importance, the molecular mechanisms of its intrinsic azole resistance have not been elucidated yet. The aim of this work was to establish if the Rhizopus oryzaeCYP51 genes are uniquely responsible for intrinsic voriconazole and fluconazole resistance in these fungal pathogens. Two CYP51 genes were identified in the R. oryzae genome. We classified them as CYP51A and CYP51B based on their sequence similarity with other known fungal CYP51 genes. Later, we obtained a chimeric Aspergillus fumigatus strain harboring a functional R. oryzae CYP51A gene expressed under the regulation of the wild-type A. fumigatusCYP51A promoter and terminator. The mutant was selected after transformation by using a novel procedure taking advantage of the FLC hypersusceptibility of the A. fumigatusCYP51A deletion mutant used as the recipient strain. The azole susceptibility patterns of the A. fumigatus transformants harboring R. oryzae CYP51A mimicked exactly the azole susceptibility patterns of this mucormycete. The data presented in this work demonstrate that the R. oryzae CYP51A coding sequence is uniquely responsible for the R. oryzae azole susceptibility patterns.


Subject(s)
Drug Resistance, Fungal/genetics , Fungal Proteins/genetics , Gene Expression Regulation, Fungal , Open Reading Frames , Rhizopus/genetics , Sterol 14-Demethylase/genetics , Antifungal Agents/pharmacology , Aspergillus fumigatus/drug effects , Aspergillus fumigatus/genetics , Aspergillus fumigatus/metabolism , Fluconazole/pharmacology , Fungal Proteins/metabolism , Humans , Isoenzymes/genetics , Isoenzymes/metabolism , Mucormycosis/microbiology , Mutation , Phylogeny , Rhizopus/classification , Rhizopus/drug effects , Rhizopus/isolation & purification , Sterol 14-Demethylase/metabolism , Voriconazole/pharmacology
16.
Article in English | MEDLINE | ID: mdl-30082288

ABSTRACT

One of the most recently described Aspergillus fumigatusCYP51A-mediated azole resistance mechanisms is TR46 Y121F T289A. Clinical A. fumigatus strains harboring these substitutions have been reported worldwide, with the exception of South America. We describe the first clinical A. fumigatus strain with this resistance mechanism isolated from an Argentinian patient. The strain was isolated in 2009 (1 year after the first-described mutant in United States), demonstrating that these alleles were scattered worldwide earlier than previously thought.


Subject(s)
Antifungal Agents/pharmacology , Aspergillus fumigatus/genetics , Azoles/pharmacology , Aspergillus fumigatus/drug effects , Drug Resistance, Fungal/genetics , Fungal Proteins/genetics , Mutation/genetics , South America
17.
Article in English | MEDLINE | ID: mdl-28461313

ABSTRACT

The echinocandin susceptibilities of 122 Candida glabrata complex strains (including 5 Candida nivariensis and 3 Candida bracarensis strains) were evaluated by microdilution and compared with the results from a molecular tool able to detect FKS mutations. No echinocandin resistance was detected. The PCR results coincide with the MIC data in 99.25% of the cases (1 C. glabrata strain was misidentified as resistant) but were 20 h faster. C. nivariensis FKS genes were sequenced and showed differences with C. glabrataFKS genes.


Subject(s)
Antifungal Agents/pharmacology , Candida glabrata/drug effects , Echinocandins/pharmacology , Candida , Candida glabrata/genetics , Candidiasis/genetics , Drug Resistance, Fungal/genetics , Microbial Sensitivity Tests , Mutation/genetics , Polymerase Chain Reaction
18.
Article in English | MEDLINE | ID: mdl-28483957

ABSTRACT

A total of 59 Candida parapsilosis sensu stricto and 1 Candida orthopsilosis recovered from catheters and blood cultures of pediatric patients from the northeastern region of Argentina were studied. Susceptibility to azoles, amphotericin B, and echinocandins was tested by the broth microdilution method. According to CLSI clinical breakpoints, >91% of the strains were azole susceptible, whereas 15% showed high amphotericin B MICs.


Subject(s)
Antifungal Agents/pharmacology , Candida parapsilosis/drug effects , Amphotericin B/pharmacology , Azoles/pharmacology , Candidemia/microbiology , Echinocandins/pharmacology , Humans , Polymerase Chain Reaction , Prohibitins
19.
Article in English | MEDLINE | ID: mdl-28242659

ABSTRACT

Candida guilliermondii shows intrinsic reduced echinocandin susceptibility. It harbors two polymorphisms (L633M and T634A) in the Fks1p hot spot 1 region. Our objective was to confirm that the reduced echinocandin susceptibility of C. guilliermondii is due to those naturally occurring substitutions. We constructed a Saccharomyces cerevisiae mutant in which a region of the FKS1 gene (including hot spot 1) was replaced with that from C. guilliermondii The chimeric mutants showed 32-fold increases in echinocandin MIC values, confirming the hypothesis.


Subject(s)
Antifungal Agents/pharmacology , Candida/drug effects , Candida/genetics , Candidiasis/drug therapy , Echinocandins/pharmacology , Glucosyltransferases/genetics , Membrane Proteins/genetics , Saccharomyces cerevisiae Proteins/genetics , Saccharomyces cerevisiae/genetics , Amino Acid Substitution/genetics , Base Sequence , Drug Resistance, Fungal/genetics , Echinocandins/genetics , Microbial Sensitivity Tests , Polymorphism, Single Nucleotide/genetics , Saccharomyces cerevisiae/drug effects
20.
Antimicrob Agents Chemother ; 60(9): 5420-6, 2016 09.
Article in English | MEDLINE | ID: mdl-27381395

ABSTRACT

Aspergillus fumigatus intrinsic fluconazole resistance has been demonstrated to be linked to the CYP51A gene, although the precise molecular mechanism has not been elucidated yet. Comparisons between A. fumigatus Cyp51Ap and Candida albicans Erg11p sequences showed differences in amino acid residues already associated with fluconazole resistance in C. albicans The aim of this study was to analyze the role of the natural polymorphism I301 in Aspergillus fumigatus Cyp51Ap in the intrinsic fluconazole resistance phenotype of this pathogen. The I301 residue in A. fumigatus Cyp51Ap was replaced with a threonine (analogue to T315 at Candida albicans fluconazole-susceptible Erg11p) by changing one single nucleotide in the CYP51A gene. Also, a CYP51A knockout strain was obtained using the same parental strain. Both mutants' antifungal susceptibilities were tested. The I301T mutant exhibited a lower level of resistance to fluconazole (MIC, 20 µg/ml) than the parental strain (MIC, 640 µg/ml), while no changes in MIC were observed for other azole- and non-azole-based drugs. These data strongly implicate the A. fumigatus Cyp51Ap I301 residue in the intrinsic resistance to fluconazole.


Subject(s)
Antifungal Agents/pharmacology , Aspergillus fumigatus/drug effects , Candida albicans/drug effects , Cytochrome P-450 Enzyme System/metabolism , Fluconazole/pharmacology , Fungal Proteins/metabolism , Mutation , Amino Acid Substitution , Aspergillus fumigatus/enzymology , Aspergillus fumigatus/genetics , Base Sequence , Candida albicans/enzymology , Candida albicans/genetics , Cytochrome P-450 Enzyme System/chemistry , Cytochrome P-450 Enzyme System/genetics , Drug Resistance, Fungal/genetics , Fungal Proteins/chemistry , Fungal Proteins/genetics , Isoleucine/chemistry , Isoleucine/metabolism , Threonine/chemistry , Threonine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL